
Alexandro Jose MartagÃ³n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8203349/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of a Web Platform to Record Lifestyle Habits in Subjects at Risk of Developing Type 2 Diabetes in a Middle-Income Population: Prospective Interventional Study. JMIR Diabetes, 2022, 7, e25105.	0.9	4
2	Increased visceral fat accumulation modifies the effect of insulin resistance on arterial stiffness and hypertension risk. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 506-517.	1.1	18
3	LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred. Lipids in Health and Disease, 2021, 20, 70.	1.2	13
4	Familial hypercholesterolemia in Mexico: Initial insights from the national registry. Journal of Clinical Lipidology, 2021, 15, 124-133.	0.6	12
5	Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health. Clinical Nutrition, 2020, 39, 1613-1621.	2.3	37
6	Prediction of incident hypertension and arterial stiffness using the non–insulinâ€based metabolic score for insulin resistance (METSâ€IR) index. Journal of Clinical Hypertension, 2019, 21, 1063-1070.	1.0	34
7	<p>Empowerment of patients with type 2 diabetes: current perspectives</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1311-1321.	1.1	40
8	The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-size adipocytes. European Journal of Endocrinology, 2019, 180, 99-107.	1.9	19
9	METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. European Journal of Endocrinology, 2018, 178, 533-544.	1.9	173
10	Noncholestatic acute hepatocellular injury following candesartan administration. British Journal of Clinical Pharmacology, 2018, 84, 204-207.	1.1	7
11	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis, 2018, 277, 234-255.	0.4	163
12	The development of the Mexican Familial Hypercholesterolemia (FH) National Registry. Atherosclerosis, 2018, 277, 517-523.	0.4	3
13	Mexican Carriers of the <i>HNF1A</i> p.E508K Variant Do Not Experience an Enhanced Response to Sulfonylureas. Diabetes Care, 2018, 41, 1726-1731.	4.3	14
14	Identification of a threshold to discriminate fasting hypertriglyceridemia with postprandial values. Lipids in Health and Disease, 2018, 17, 156.	1.2	9
15	The panorama of familial hypercholesterolemia in Latin America: a systematic review. Journal of Lipid Research, 2016, 57, 2115-2129.	2.0	24
16	The Amelioration of Hepatic Steatosis by Thyroid Hormone Receptor Agonists Is Insufficient to Restore Insulin Sensitivity in Ob/Ob Mice. PLoS ONE, 2015, 10, e0122987.	1.1	29
17	Pharmacological Activation of Thyroid Hormone Receptors Elicits a Functional Conversion of White to Brown Fat. Cell Reports, 2015, 13, 1528-1537.	2.9	96
18	Opening the Black Box: Revealing the Molecular Basis of Thyroid Hormone Transport. Endocrinology, 2013, 154, 2266-2269.	1.4	2

#	Article	IF	CITATIONS
19	Thyroid Hormone Receptor Agonists Reduce Serum Cholesterol Independent of the LDL Receptor. Endocrinology, 2012, 153, 6136-6144.	1.4	56
20	Group A Streptococcus emm Gene Types in Pharyngeal Isolates, Ontario, Canada, 2002–2010. Emerging Infectious Diseases, 2011, 17, 2010-7.	2.0	65
21	Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5039-5044.	3.3	90